Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
|Webcasts|November 7, 2019
How to Approach Preparative LC for Compound Purification in the Research and Development Laboratory
Author(s)Thermo Fisher Scientific
Ready to scale-up your analytical LC method to prep LC and not sure where to start? Join our webcast to discover how to select the right preparative HPLC column to meet your application needs. Live: Thursday, Nov. 7, 2019 at 11am EST | 8am PST | 4pm GMT | 5pm CET On demand available after airing until Nov. 7, 2020 Register free
Register free:
Event Overview:
In this webcast, learn about the wide variety of phases, hardware, and method development tools available to help you chose the most appropriate preparative HPLC column. Choosing the right preparative LC column packed with the right stationary phases and in the right hardware will help you maximize your performance.
Key Learning Objectives:
- Discover how to easily scale your method from analytical to prep LC
- Introduction to the Thermo Scientific Preparative HPLC phases
- Understand the different hardware types to suit your prep LC requirements
Speakers: Mike Baynham, PhD, Senior Product Manager – LC Columns, Thermo Fisher Scientific
Rainer Bauder, PhD, Manager, Technical Applications – Chromatography Columns & Consumables, Thermo Fisher Scientific
Time and Date: Thursday, Nov. 7, 2019 at 11am EST | 8am PST | 4pm GMT | 5pm CET
On demand available after airing until Nov. 7, 2020
Sponsor: Thermo Fisher Scientific
Register free:
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.